Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors

• Published in: Frontiers in oncology Vol. 13; p. 1276009
• Main Authors: Xue, Liqiong, Tang, Wenbo, Zhou, Jiuli, Xue, Junli, Li, Qun, Ge, Xiaoxiao, Lin, Fengjuan, Zhao, Wei, Guo, Ye
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 23.10.2023
• Subjects: cyclin-dependent kinase inhibitor 2A; head and neck squamous cell carcinoma; immunotherapy; next-generation sequencing; Oncology; prognosis

Background This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy. Methods In this retrospective s...